earnings
confidence high
sentiment positive
materiality 0.75
Amgen Q2 2026 revenue up 10% to $10.1B; GAAP EPS $4.37 (+65%), non-GAAP EPS $6.29 (+4%)
AMGEN INC
- Total revenues $10.1B (+10% YoY); product sales +9% driven by volume growth.
- GAAP EPS $4.37 (+65% from $2.65); non-GAAP EPS $6.29 (+4% from $6.02).
- GAAP operating margin 36.8% (+6.5pp); non-GAAP operating margin 48.4% (-0.5pp).
- Free cash flow $3.5B vs $1.9B in Q2 2025, helped by final repatriation tax payment timing.
- Six key growth drivers +26% YoY, ~70% of product sales; 22 products double-digit growth.